Key result
Autoimmune congenital heart block is a severe condition with a global mortality rate of 20% and pacemaker requirement rates of at least 64%, often within the first year of life.
This review highlights the complex clinical scenarios of autoimmune congenital heart block, which carries a 20% global mortality rate and high pacemaker requirement.
Alerts clinicians to complex ACHB cases needing multidisciplinary vigilance; leaves open questions on atypical autoimmunity and assisted reproduction risks.
Autoimmune congenital heart block (ACHB) is an immune-mediated cardiac disease included among the manifestations collectively referred to as neonatal lupus. The placental transference of maternal Ro/La autoantibodies may damage the conduction tissues during fetal development leading to blocking of signal conduction at the atrioventricular (AV) node in an otherwise structurally normal heart. Irreversible complete AV block is the main cardiac manifestation of ACHB, but some babies may develop endocardial fibroelastosis, valvular insufficiency, and/or frank cardiomyopathies with significantly reduced cardiac function requiring transplant. The severity of ACHB is illustrated by a global mortality rate of 20% and pacemaker rates of at least 64%, often within the first year of life. This review analyses the main complex and/or unusual clinical situations associated with ACHB, including unusual maternal immunological profiles, infrequent maternal autoimmune diseases, cardiac damage unrelated to AV block, fetal invasive management, late complications after birth, risk of congenital heart block (CHB) in ovodonation and in vitro fertilization techniques, the role of maternal features other than autoimmunity, the influence of the birth order or the risk of CHB in twins and triplets.
No takes yet. Share an insight, caveat, or question.
Brito‐Zerón et al. (2016) conducted a review in Autoimmune congenital heart block. Autoimmune congenital heart block was evaluated. Autoimmune congenital heart block is a severe condition with a global mortality rate of 20% and pacemaker requirement rates of at least 64%, often within the first year of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: